SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.
COVID-19
Health and Demographic Surveillance System
IgG antibody
Kenya
SARS-CoV-2
seroprevalence
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
19
06
2023
received:
05
04
2023
accepted:
28
06
2023
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
26
9
2023
Statut:
ppublish
Résumé
We sought to estimate SARS-CoV-2 antibody seroprevalence within representative samples of the Kenyan population during the third year of the COVID-19 pandemic and the second year of COVID-19 vaccine use. We conducted cross-sectional serosurveys among randomly selected, age-stratified samples of Health and Demographic Surveillance System (HDSS) residents in Kilifi and Nairobi. Anti-spike (anti-S) immunoglobulin G (IgG) serostatus was measured using a validated in-house ELISA and antibody concentrations estimated with reference to the WHO International Standard for anti-SARS-CoV-2 immunoglobulin. HDSS residents were sampled in February-June 2022 (Kilifi HDSS N = 852; Nairobi Urban HDSS N = 851) and in August-December 2022 (N = 850 for both sites). Population-weighted coverage for ≥1 doses of COVID-19 vaccine were 11.1% (9.1-13.2%) among Kilifi HDSS residents by November 2022 and 34.2% (30.7-37.6%) among Nairobi Urban HDSS residents by December 2022. Population-weighted anti-S IgG seroprevalence among Kilifi HDSS residents increased from 69.1% (65.8-72.3%) by May 2022 to 77.4% (74.4-80.2%) by November 2022. Within the Nairobi Urban HDSS, seroprevalence by June 2022 was 88.5% (86.1-90.6%), comparable with seroprevalence by December 2022 (92.2%; 90.2-93.9%). For both surveys, seroprevalence was significantly lower among Kilifi HDSS residents than among Nairobi Urban HDSS residents, as were antibody concentrations (p < 0.001). More than 70% of Kilifi residents and 90% of Nairobi residents were seropositive for anti-S IgG by the end of 2022. There is a potential immunity gap in rural Kenya; implementation of interventions to improve COVID-19 vaccine uptake among sub-groups at increased risk of severe COVID-19 in rural settings is recommended.
Sections du résumé
BACKGROUND
BACKGROUND
We sought to estimate SARS-CoV-2 antibody seroprevalence within representative samples of the Kenyan population during the third year of the COVID-19 pandemic and the second year of COVID-19 vaccine use.
METHODS
METHODS
We conducted cross-sectional serosurveys among randomly selected, age-stratified samples of Health and Demographic Surveillance System (HDSS) residents in Kilifi and Nairobi. Anti-spike (anti-S) immunoglobulin G (IgG) serostatus was measured using a validated in-house ELISA and antibody concentrations estimated with reference to the WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
RESULTS
RESULTS
HDSS residents were sampled in February-June 2022 (Kilifi HDSS N = 852; Nairobi Urban HDSS N = 851) and in August-December 2022 (N = 850 for both sites). Population-weighted coverage for ≥1 doses of COVID-19 vaccine were 11.1% (9.1-13.2%) among Kilifi HDSS residents by November 2022 and 34.2% (30.7-37.6%) among Nairobi Urban HDSS residents by December 2022. Population-weighted anti-S IgG seroprevalence among Kilifi HDSS residents increased from 69.1% (65.8-72.3%) by May 2022 to 77.4% (74.4-80.2%) by November 2022. Within the Nairobi Urban HDSS, seroprevalence by June 2022 was 88.5% (86.1-90.6%), comparable with seroprevalence by December 2022 (92.2%; 90.2-93.9%). For both surveys, seroprevalence was significantly lower among Kilifi HDSS residents than among Nairobi Urban HDSS residents, as were antibody concentrations (p < 0.001).
CONCLUSION
CONCLUSIONS
More than 70% of Kilifi residents and 90% of Nairobi residents were seropositive for anti-S IgG by the end of 2022. There is a potential immunity gap in rural Kenya; implementation of interventions to improve COVID-19 vaccine uptake among sub-groups at increased risk of severe COVID-19 in rural settings is recommended.
Identifiants
pubmed: 37752065
doi: 10.1111/irv.13173
pmc: PMC10522478
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13173Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 214320
Pays : United Kingdom
Organisme : Bill & Melinda Gates Foundation
ID : INV-039626
Pays : United States
Informations de copyright
© 2023 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
Influenza Other Respir Viruses. 2023 Sep;17(9):e13173
pubmed: 37752065
Influenza Other Respir Viruses. 2022 Jan;16(1):7-13
pubmed: 34611986
BMJ Glob Health. 2022 Aug;7(8):
pubmed: 35998978
Lancet Glob Health. 2021 Jun;9(6):e724-e725
pubmed: 33711261
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
JAMA. 2021 Oct 12;326(14):1436-1438
pubmed: 34473191
PLOS Glob Public Health. 2022 Aug 18;2(8):e0000883
pubmed: 36962821
Int J Infect Dis. 2021 Dec;113:58-64
pubmed: 34597764
N Engl J Med. 2022 Apr 7;386(14):1314-1326
pubmed: 35196424
Vaccine. 2022 Jan 21;40(2):306-315
pubmed: 34933765
Int J Epidemiol. 2012 Jun;41(3):650-7
pubmed: 22544844
Int J Epidemiol. 2015 Apr;44(2):462-71
pubmed: 25596586
Nat Rev Immunol. 2022 Oct;22(10):591-592
pubmed: 35945353